O
Opus Genetics, Inc. (IRD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$4.04
+0.06 (+1.51%)
Market Cap: $384.68M
Last updated: Nov 17, 2026 at 11:06 AM ET
Opus Genetics, Inc. (IRD) Valuation Multiples
Opus Genetics (IRD) trades at 52.0x sales and 10.7x book value. Its P/B of 10.7x is above its 5-year median of 2.9x. Its forward P/E is 12.0x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 12.0x |
| Price to sales | 52.0x |
| Price to book | 10.7x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/B is 234.4% above 3.2x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 10.7x | 2.9x | 3.2x |
Valuation History
Over the 4 of the 10 year ends shown that have a P/S, its P/S ranged from 1.9x in 2022 to 9.0x in 2025. 2025 was the highest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $2.01 | N/A | 9.0x | 81.5x |
| 2024 | $1.19 | N/A | 3.0x | 5.6x |
| 2023 | $3.01 | N/A | 3.4x | 1.3x |
| 2022 | $3.53 | 4.1x | 1.9x | 6.1x |
| 2021 | $3.73 | N/A | N/A | 3.1x |
| 2020 | $6.49 | N/A | N/A | 4.3x |
| 2019 | $7.64 | N/A | N/A | 0.7x |
| 2018 | $44.66 | N/A | N/A | 4.6x |
| 2017 | $97.00 | N/A | N/A | 3.8x |
| 2016 | $68.14 | N/A | N/A | 1.8x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About IRD
What is IRD's forward P/E ratio?
Opus Genetics has a forward P/E ratio of 12.0x.
Is IRD stock overvalued?
GNG's valuation label for IRD is Overvalued.
What is IRD's price to sales ratio?
Opus Genetics has a price to sales ratio of 52.0x.
IRD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors